Urticaria and COVID-19
DOI:
https://doi.org/10.47196/da.v28i1.2248Keywords:
urticaria, COVID-19, SARS-CoV-2Abstract
Urticaria is a disease characterized by the development of erythematous and evanescent hives, angioedema or both, which affects between 0.3% and 20% of the population worldwide. As many other diseases, the epidemiology, clinical manifestations, diagnosis and management of urticaria have undergone changes in the context of the COVID-19 pandemic and deserve consideration towards vaccines for SARS-CoV-2 implementation. The objective of this paper is to compile the available information reported to date on the relationship between this inflammatory pathology and this viral disease.
References
I. Larenas-Linnemann DES, Parisi CAS, Ritchie C, Cardona-Villa R, et ál. Update on omalizumab for urticaria: what’s new in the literature from mechanisms to clinic. Curr Allergy Asthma Rep. 2018;18:33.
II. Parisi CA, Ritchie C, Petriz N, Morelo-Torres CM, et ál. Chronic urticaria in a health maintenance organization of Buenos Aires, Argentina. New data that increase global knowledge of this disease. An Bras Dermatol. 2018;93:76-79.
III. Maurer M, Zuberbier T, Metz M. The classification, pathogenesis, diagnostic workup, and management of urticaria: an update. Handb Exp Pharmacol. 2021. Epub ahead to print.
IV. Wedi B, Raap U, Wieczorek D, Kapp A. Urticaria and infections. Allergy Asthma Clin Immunol. 2009;5:10.
V. Imbalzano E, Casciaro M, Quartuccio S, Minciullo PL, et ál. Association between urticaria and virus infections: A systematic review. Allergy Asthma Proc. 2016;37:18-22.
VI. Leiste A, Skaletz-Rorowski A, Venten I, Altmeyer P, et ál. Urticaria associated with Norovirus infection: Report of two cases. J Dtsch Dermatol Ges. 2008;6:563-565.
VII. Kempuraj D, Selvakumar GP, Ahmed ME, Raikwar SP, et ál. COVID-19, mast cells, cytokine storm, psychological stress, and neuroinflammation. Neuroscientist. 2020;26:402-414.
VIII. Kritas SK, Ronconi G, Caraffa A, Gallenga CE, et ál. Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy. J Biol Regul Homeost Agents. 2020;34:9-14.
IX. Guan WJ, Ni ZY, Hu Y, Liang WH, et ál. Clinical characteristics of coronavirus disease 2019. N Engl J Med. 2020;382:1708-1720.
X. Larenas-Linnemann D, Luna-Pech J, Navarrete-Rodríguez EM, Rodríguez-Pérez N, et ál. Cutaneous manifestations related to COVID-19 immune dysregulation in the pediatric age group. Curr Allergy Asthma Rep. 2021;21:13.
XI. Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, et ál. The spectrum of COVID-19-associated dermatologic manifestations: An international registry of 716 patients from 31 countries. J Am Acad Dermatol. 2020;83:1118-1129.
XII. González-González F, Cortés-Correa C, Peñaranda-Contreras E. Cutaneous manifestations in patients with COVID-19: clinical characteristics and possible pathophysiologic mechanisms. Actas Dermosifiliogr. 2021;112:314-323.
XIII. Carrascosa JM, Morillas V, Bielsa I, Munera-Campos M. Cutaneous manifestations in the context of SARS-CoV-2 infection (COVID-19). Actas Dermosifiliogr. 2020;11:734-742.
XIV. Henry D, Ackerman M, Sancelme E, Finon A, et ál. Urticarial eruption in COVID‐19 infection. J Eur Acad Dermatol Venereol. 2020:34:e244-e245.
XV. Quintana-Castanedo L, Feito-Rodríguez M, Valero-López I, Chiloeches-Fernández C, et ál. Urticarial exanthem as early diagnostic clue for COVID-19 infection. JAAD Case Rep. 2020;6:498-499.
XVI. Veraldi S, Romagnuolo M, Benzecry V. Urticaria as a first clinical manifestation of COVID-19. Eur J Dermatol. 2020;30:737-738.
XVII. van Damme C, Berlingin E, Saussez S, Accaputo O. Acute urticaria with pyrexia as the first manifestations of a COVID-19 infection. J Eur Acad Dermatol Venereol. 2020;34:e300-301.
XVIII. Hassan K. Urticaria and angioedema as a prodromal cutaneous manifestation of SARS-CoV-2 (COVID-19) infection. BMJ Case Rep. 2020;13:e236981.
XIX. Najafzadeh M, Shahzad F, Ghaderi N, Ansari K, et ál. Urticaria (angioedema) and COVID-19 infection. J Eur Acad Dermatol Venereol. 2020;34:e568-570.
XX. 20. Abasaeed Elhag SA, Ibrahim H, Abdelhadi S. Angioedema and urticaria in a COVID-19 patient: A case report and review of the literature. JAAD Case Rep. 2020;6:1091-1094.
XXI. Ocampo-Candiani J, Ramos-Cavazos CJ, Arellano-Mendoza MI, Arenas-Guzmán R, et ál. International registry of dermatological manifestations secondary to COVID‐19 infection in 347 Hispanic patients from 25 countries. Int J Dermatol. 2021;30:956-963.
XXII. Galván-Casas C, Català A, Carretero-Hernández G, Rodríguez-Jiménez P, et ál. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183:71-77.
XXIII. Daneshgaran G, Dubin DP, Gould DJ. Cutaneous manifestations of COVID-19: an evidence-based review. Am J Clin Dermatol. 2020;21:627-639.
XXIV. Andina D, Belloni-Fortina A, Bodemer C, Bonifazi E, et ál. Skin manifestations of COVID-19 in children: Part 2. Clin Exp Dermatol. 2021;46:451-461.
XXV. Algaadi SA. Urticaria and COVID-19: A review. Dermatol Ther. 2020;33:e14290.
XXVI. Torres T, Puig L. Managing cutaneous immune-mediated diseases during the COVID-19 pandemic. Am J Clin Dermatol. 2020;21:307-311.
XXVII. Rodríguez-Jiménez P, Chicharro P, De Argila D, Muñoz-Hernández P, et ál. Urticaria‐like lesions in COVID‐19 patients are notnreally urticaria. A case with clinicopathological correlation. J Eur Acad Dermatol Venereol. 2020;34:e459-e460.
XXVIII. Amatore F, Macagno N, Mailhe M, Demarez B, et ál. SARS‐CoV‐2 infection presenting as a febrile rash. J Eur Acad Dermatol Venereol. 2020;34:e304-e306.
XXIX. Perosanz-Lobo D, Fernández-Nieto D, Burgos-Blasco P, Selda-Enriquez G, et ál. Urticarial vasculitis in COVID‐19 infection: a vasculopathy‐related symptom? J Eur Acad Dermatol Venereol. 2020;34:e566-e568.
XXX. Criado PR, Criado RFJ, Pincelli TP, Yoshimoto TA, et ál. Chronic spontaneous urticaria exacerbation in a patient with COVID‐19: rapid and excellent response to omalizumab. Int J Dermatol. 2020;59:1294-1295.
XXXI. Kaushik A, Parsad D, Kumaran MS. Urticaria in the times of COVID-19. Dermatol Ther. 2020;33:e13817.
XXXII. Maláska J, Stašek J, Duška F, Balík M, et ál. Effect of dexamethasone in patients with ARDS and COVID-19 - prospective, multi-centre, open-label, parallel-group, randomized controlled trial (REMED trial): A structured summary of a study protocol for a randomized controlled trial. Trials. 2021;22:172.
XXXIII. Abuelgasim E, Dona ACM, Sondh RS, Harky A. Management of urticaria in COVID-19 patients: A systematic review. Dermatol Ther. 2021;34:e14328.
XXXIV. Patsatsi A, Kyriakou A. Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: What’s the evidence? Clin Dermatol. 2021;39:52-55.
XXXV. Kocatürk E, Salman A, Cherrez-Ojeda I, Criado PR, et ál. The global impact of the COVID-19 pandemic on the management and course of chronic urticaria. Allergy. 2021;76:816-830.
XXXVI. Cardinale F, Ciprandi G, Barberi S, Bernardini R, et ál. Consensus statement of the Italian society of pediatric allergy and immunology for the pragmatic management of children and adolescents with allergic or immunological diseases during the COVID-19 pandemic. Ital J Pediatr. 2020;46:84.
XXXVII. Hawro T, Ohanyan T, Schoepke N, Metz M, et ál. The urticarial activity score. Validity, reliability, and responsiveness. J Allergy Clin Immunol Pract. 2018;6:1185-1190.
XXXVIII. Weller K, Groffik A, Church MK, Hawro T, et ál. Development and validation of the Urticaria Control Test: A patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol. 2014;133:1365-1372.
XXXIX. García-Díez I, Curto-Barredo L, Weller K, Pujol RM, et ál. Cross-cultural adaptation of the Urticaria Control Test from German to Castilian Spanish. Actas Dermosifiliogr. 2015;106:746-752.
XL. Bansal CJ, Bansal AS. Stress, pseudoallergens, autoimmunity, infection and inflammation in chronic spontaneous urticaria. Allergy Asthma Clin Immunol. 2019:11;15:56.
XLI. Tuchinda P, Kulthanan K, Chularojanamontri L, Arunkajohnsak S, et ál. Relationship between vitamin D and chronic spontaneous urticaria: a systematic review. Clin Transl Allergy. 2018;8:51.
XLII. Sun Q, Fathy R, McMahon DE, Freeman EE. COVID-19 vaccines and the skin: The landscape of cutaneous vaccine reactions worldwide. Dermatol Clin. 2021;39:653-673.
XLIII. Turner PJ, Ansotegui IJ, Campbell DE, Cardona V, et ál. COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee. World Allergy Organ J. 2021;14:100517.
XLIV. Cardona V, Ansotegui IJ, Ebisawa M, El-Gamal Y, et ál. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J. 2020;13:100472.
XLV. McMahon DE, Amerson E, Rosenbach M, Lipoff JB, et ál. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. J Am Acad Dermatol. 2021;85:46-55.
XLVI. Moreno P, Docena G, Biglione M, Onetti C. et ál. Posicionamiento de la AAAeIC en relación a la vacunación COVID-19 en pacientes alérgicos del 11 de marzo 2021. Disponible en: https://www.alergia.org.ar/index.php/institucional/sobreaaaeic/newsletter/posicionamiento-de-la-aaaeic-en-relacion-a-la-vacunacion-covid-19-en-pacientes-alergicos [Consultado noviembre 2021].
XLVII. Campaña Nacional de Vacunación contra la COVID-19. 15° Informe de vigilancia de seguridad en vacunas (CoNaSeVa) En: https://bancos.salud.gob.ar/recurso/15-informe-de-vigilancia-de-seguridad-en-vacunas. [Consultado noviembre 2021].
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Dermatología Argentina
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
El/los autor/es tranfieren todos los derechos de autor del manuscrito arriba mencionado a Dermatología Argentina en el caso de que el trabajo sea publicado. El/los autor/es declaran que el artículo es original, que no infringe ningún derecho de propiedad intelectual u otros derechos de terceros, que no se encuentra bajo consideración de otra revista y que no ha sido previamente publicado.
Le solicitamos haga click aquí para imprimir, firmar y enviar por correo postal la transferencia de los derechos de autor
